IPAV wishes to congratulate one of its most charismatic and impactful Advisory Board members, Prof Jeff Karp on an extraordinary study evaluating a novel gel that provides targeted delivery of a therapeutic for the treatment of Irritable Bowel Disorder (IBD). The findings of the study were published in Science Translational Medicine.

We wish Prof Karp and his team our very best wishes in the next stage of clinical trials, and hope that we can be of assistance to fellow innovators seeking to navigate the complex regulatory pathway for combinational therapeutics.